Introduction
MSCs are also referred to as multipotent mesenchymal stromal cells, as their true 'stemness', that is, on division one daughter cell remains stem and the other is able to replenish a whole tissue compartment, has yet to be shown. 1 In any case, MSCs show classical adult stem cell multipotency in that they are capable of differentiating in vitro and in vivo to all mesenchymal lineages, including adipose, bone, cartilage, muscle and myelosupportive stroma [2] [3] [4] [5] ( Figure 1 ). MSCs may be isolated from BM, skeletal muscle, adipose tissue, synovial membranes and other connective tissues of human adults [6] [7] [8] [9] as well as cord blood 10 and placental products, 11 and are defined by using a combination of phenotypic markers and functional properties. Controversy still exists over the in vivo phenotype of MSCs; however, in addition to their multipotentiality, ex vivo expanded MSCs can be identified by flow cytometry as cells that stain positive for CD73, CD90 and CD105 while they do not express the hematopoietic markers CD14, CD34, CD45 and MHC class II. 12 In vitro, MSCs have vast proliferative potential, can clonally regenerate, and can give rise to differentiated progeny. They also exhibit anti-proliferative and antiinflammatory properties in vitro and in vivo, making them candidates for the treatment of acute inflammatory AD. 13, 14 Regardless of whether or not MSCs are true stem cells, clinical benefit from MSCs may not require sustained engraftment of large numbers of cells or differentiation into specific tissues. It is possible that a therapeutic benefit can be obtained by local paracrine production of growth factors and a provision of temporary antiproliferative and immunomodulatory properties. 15, 16 
MSCs immunomodulatory properties
Until recently it was assumed that MSCs enjoyed immune privilege in allogeneic settings 17 neither exerting nor being subject to immunological reaction, but recent data suggest that in a non-immunosuppressed host, allogeneic MSCs may be eliminated, 18 especially if gene-transfected. 19 In vitro results indicate that MSCs possess immunosuppressive properties. Rodent, baboon and human MSCs suppress T-and B-cell lymphocyte proliferation in MLCs or are induced by mitogens and antibodies in a dosedependent manner. [20] [21] [22] [23] [24] [25] [26] [27] [28] The suppression is MHC independent, and in human cell cultures the magnitude of suppression is not reduced when the MSCs are separated from the lymphocytes in transwells, indicating that cell-cell contact is not required. 20, 22, 26, [28] [29] [30] However, not all experiments have shown antiproliferative effects. In some studies the influence of BM MSCs on highly purified B cells resulted in the promotion of proliferation and differentiation into Ig-secreting cells. 31, 32 These controversial conclusions are likely to be the result of specific experimental conditions possibly involving pure lymphocyte populations. Regardless of in vitro studies, in vivo administration of MSCs led to the inhibition of pathogenic antibodies. 33, 34 This effect was recently shown to be the result of metalloproteinase processing of CCL2 produced by MSCs, resulting in the suppression of STAT3. 34 
Mechanisms of inhibition of the immune response
The mechanism(s) underlying the immunosuppressive effect remain to be fully explained with, sometimes conflicting, data. Initially, the fact that MSCs, when exposed to IFN-g, express class II Ag but never costimulation molecules, 35 suggested that inhibition of T-cell response may be related to the induction of anergy or apoptosis in cell-cell contact conditions. However, apart from one publication reporting of MSC-induced apoptosis of proliferating lymphocytes, 36 most publications not only excluded the involvement of MSC-induced apoptosis of target cells but, in contrast, suggested that the arrest of apoptosis may be a major mechanism for MSCs imparting a survival signal to immune cells 28, 37 as well as to other cells. 38 Clearly, a major mechanism leading to the inhibition of immune-cell effector functions is the arrest of the cell cycle in G0/G1, which results in the inhibition of cell proliferation. [26] [27] [28] 38 Whether this effect is mediated by cell contact mechanisms or soluble factors is still not fully understood. However, transwell experiments have shown putative paracrine soluble factors (Table 1) including hepatocyte growth factor (HGF) and transforming growth factor-b1 (TGF-b1), 22 prostaglandin E 2 39,30 indoleamine 2,3-deoxygenase, 40 inducible NO synthetase resulting in Stat 5 inhibition in lymphocytes, 41 soluble HLA-G 42 and soluble IL-1 receptor. 43 Current data, however, show that these molecules play only a limited role and others are yet to be discovered.
Fate of transplanted MSCs in vivo
There are scarce data. In animals, radiolabelling experiments in rats show localization after intraarterial and i.v. infusion mostly in lungs and secondarily in liver and other organs. 44 More detailed studies in three baboons (two using autologous and one allogeneic MSC) and using the green fluorescent protein retroviral construct showed that gastrointestinal tissues harboured high concentrations of transgene per microgram of DNA. Additional tissues including kidney, lung, liver, thymus, and skin were also found to contain relatively high amounts of DNA equivalents. Estimated levels of engraftment in these tissues ranged from 0.1 to 2.7%, similar to the autologous and allogeneic experiments. 45 Active homing of MSCs to BM occurs largely because of the stromal-derived factor-1 (SDF-1) interacting with CXCR4 on the MSC surface 46 and similar mechanisms are operational in pancreatic islets 47 as well as in ischemic tissue. 48 In general, mobilization of chemokine receptors expressing MSCs and their subsequent homing to injured tissues depends on cytokines, chemokines and growth factors released during systemic and local inflammatory conditions, 49 and is mediated by the coordinated 
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Soluble HLA-G Nasef et al. interaction between integrins and selectins expressed by MSCs and endothelial cells. 50 Indeed, following i.v. administration, MSCs can reach the inflamed central nervous system (CNS) where they exert a potent therapeutic effect. 33 If active homing of MSCs to inflamed and ischemic tissues were the case, this would increase the feasibility of cellular therapy for AD as, independent of the putative soluble factor(s) produced by them, they would be delivered directly into the target tissue, reducing the need for using either large numbers of MSCs or high concentrations of biological agents systemically.
A new initiative is to modify surface structures on MSCs to increase their penetration and integration into specific target tissues. It has been shown that recruitment of cells to bone occurs within specialized marrow vessels that constitutively express vascular E-selectin, a lectin that recognizes sialofucosylated determinants on its various ligands. Sackstein et al. showed that human MSCs do not express E-selectin ligands, but express a CD44 glycoform bearing a-2,3-sialyl modifications. They converted the native CD44 glycoform on MSCs into hematopoietic cell E-selectin/L-selectin ligand (HCELL) using an a-1,3-fucosyltransferase preparation and in enzymatic conditions specifically designed for treating live cells, which conferred potent E-selectin binding without effects on cell viability or multipotency. Real-time intravital microscopy in immunocompromised (NOD/SCID) mice showed that i.v. infused HCELL( þ ) MSCs infiltrated marrow within hours of infusion, with ensuing rare foci of endosteally localized cells and human osteoid generation. 51 MSC homing to tumors is of concern as shown by human MSC localization to a murine xenogenic breast cancer SCID mouse model through monocyte chemotactic protein-1 (MCP-1), 52 which while being a potential therapeutic delivery system for cancer therapy, may pose long-term safety issues in AD treatment. MSCs concentrate in radiation-damaged and ischemic tissue, 53 but as yet active homing mechanisms have not been shown. This is may be an important advantage when treating some acute inflammatory AD with accompanying critical ischemia such as vasculitis or SSc. In humans receiving sexmismatched allogeneic MSC, sex chromosomal analysis of MSC cells has shown a presence up to 12 months in the gastrointestinal tract and BM for months, though extensive data are lacking.
Animal models of tissue protection
It may be impossible, in fact meaningless, to attempt separating the anti-inflammatory from the immunomodulatory and tissue-protective 'trophic' effects of MSCs. 54 An immunosuppressive effect of MSCs in vivo was first suggested in a baboon model, in which infusion of ex vivo expanded donor or third-party MSCs delayed the time to rejection of histoincompatible skin grafts. 25 MSCs also down-regulated bleomycin-induced lung inflammation and fibrosis in murine models, if given early (but not late) after disease induction. 55 This effect was achieved through the reduction of inflammation mediated by IL-1R antagonist secreted by MSCs and capable of antagonizing IL-1a secreting T-cells and TNF-a producing macrophages. 43 Similar results were obtained by the infusion of MSCs in a murine model with acute lung injury leading to a decreased production of pro-inflammatory cytokines and increased levels of IL-10 56 and in a murine hepatic fibrosis model (carbon tetrachloride induced) using an MSC line bearing the fetal liver kinase-1 (FLK1) marker. 57 In all these studies, the protective effect of MSCs on lung cells occurred despite limited levels of engraftment in the target organ and transdifferentiation. Similarly, it was shown that MSCderived conditioned medium is enriched with many chemokines that are able to reverse fulminant hepatic failure through the inhibition of liver infiltration by leukocytes and subsequent death of hepatocytes. 58 Tissueprotective effects were also seen in a rat kidney model of ischemia/reperfusion injury in which syngeneic MSCs but not fibroblasts were used. These effects were not mediated by MSC transdifferentiation but, in contrast, by bystander mechanisms including the inhibition of pro-inflammatory cytokines and an anti-apoptotic effect on target cells. 59 In another study it was shown that the renoprotective effect of MSCs was mediated by the mitogenic and pro-survival insulin growth factor-1 (IGF-1) produced by the MSCs. 60 Recently, a vasculotropic effect of infused MSC in the kidney was shown, 61 which may be relevant to SSc. Evidence supporting the paracrine hypothesis for MSCmediated effect on target tissues was also provided by studies that showed that MSCs modified with the prosurvival gene Akt1 can rescue ischemic cardiomyocytes and restore ventricular functions. 62 Restoration of retinal function and substantial delay in retinal degeneration through inhibition of photoreceptor apoptosis was obtained through subretinal transplantation of MSCs. 63 Inhibition of apoptosis, prolonged survival and proangiogenic effects were also detected in hypoxic endothelial cells upon exposure to IL-6 and VEGF-rich MSC-derived conditioned medium. 64 Neuroprotective effects were also observed by MSC infusion in animal models of stroke.
It is noteworthy that common paracrine mechanisms, independent of transdifferentiation, appear to support MSC therapeutic plasticity for a wide range of experimental diseases.
Animal models of autoimmunity
On the basis of their immunomodulatory features together with tissue-protective properties and, possibly, some capacity of transdifferentiating, MSCs represented an ideal strategy to treat autoimmunity. The first disease in which the therapeutic potential of MSCs was addressed was experimental autoimmune encephalomyelitis (EAE), a murine model of multiple sclerosis (MS). The i.v. administration of syngeneic MSCs resulted in both clinical and histological improvement. The response was dependant on time of MSC treatment, the earlier the better, and was associated with the induction of tolerance towards the immunizing myelin Ag MOG (myelin oligodendrocyte glycoprotein). 66 In another paper, a similar amelioration was obtained utilizing human MSCs in a PLP (proteolipid protein)-induced model of EAE that engrafted inside the mouse CNS with limited evidence of transdifferentiation into neural cells. 67 Several other studies confirmed the beneficial effect of MSCs injected systemically, 33, 68 i.p. 69 or locally inside the CNS, 68 suggesting that not only do MSCs exert a potent inhibition of the autoimmune attack to the CNS but are also endowed with significant neuroprotective effects despite limited evidence of CNS infiltration (Figure 2) . 16 It is noteworthy that neural stem cells 70 and, more recently, human embryonal stem cellderived neuronal precursor cells, 71 displayed a strikingly beneficial effect upon administration in EAE-affected mice through bystander mechanisms leading to the immunomodulation of autoreactivity and neuroprotection.
Similar effects have been observed in experimental models of rheumatoid arthritis where MSCs alone, 72, 73 or genetically modified overexpressing IL10, 74 prevented tissue destruction and suppressed the autoimmune response against type II collagen.
In an experimental model of diabetes induced in mice by streptozotocin it was observed that MSCs promote endogenous repair of pancreatic islets and renal glomeruli. 75 Similarly, co-infusion of MSCs and BM cells, following sublethal irradiation, inhibited the proliferation of b-cell-specific T cells isolated from the pancreas of diabetic mice and restored insulin and glucose levels through the induction of regenerated recipient-derived pancreatic b-cells in the absence of transdifferentiation. 76 The immunosuppressive effect of MSCs on T cells was also exploited in a multi-organ autoimmunity mouse model in which MSCs homed in the mesenteric lymph nodes, significantly improving autoimmune enteropathy. 77 These results confirm the therapeutic plasticity of MSCs owing to their capacity of modulating systemic autoimmunity and protecting target tissues.
MSCs and human experience
Ex vivo-expanded allogeneic MSCs have been infused in several phase 1 studies. [78] [79] [80] [81] No adverse events during or after MSC infusion have been observed and no ectopic tissue formation has been noted. Similar to what was observed in animal models, after infusion, MSCs are likely to remain in circulation for a very short time, probably no more than an hour. 80 Although durable stromal cell chimerism has been difficult to establish, low levels of engrafted MSCs have been detected in several tissues, 79, 81, 82 confirming preclinical studies.
It is possible that sufficient therapeutic benefit is obtained by local paracrine production of growth factors and the provision of temporary immunosuppression by MSC infusion. Infusion of haploidentical MSCs into a patient with steroid-resistant severe acute GVHD of the gut and liver promptly improved liver values and intestinal function. 83 Upon discontinuation of cyclosporine, the patient's acute GVHD recurred but was still responsive to a second MSC infusion. Lymphocytes from the patient, when investigated on multiple occasions after MSC infusion, continued to proliferate against lymphocytes derived from the haploidentical MSC donor in co-culture experiments. This suggests an acute immunosuppressive effect of MSC in vivo, rather than a development of longterm tolerance. The EBMT is currently running protocols for the prevention and treatment of acute GVHD through the Developmental Committee and interim results of the treatment trial have recently been published. 84 Thirty of 55 steroid-resistant acute GVHD patients had a complete response with no immediate toxicity. A median dose of allogeneic MSC was 1.4 Â 10 6 /kg body weight up to five times. Four patients had a recurrence or de novo malignancy and complete responders had a reduced transplant-related mortality at 12 months (37% vs 72%) and higher overall 2-year survival (52% vs 16%). Although these encouraging results support an effect of infused MSCs in the prevention of GVHD, an increased occurrence of leukemia relapses has been reported because of the inhibition of leukemic cell-specific T-cell responses. 85 MSCs from human autoimmune disease Autologous BM-derived MSCs have been shown to be potently antiproliferative to stimulated T-cells from normal participants and autoimmune (RA, SSc, Sjoegren's, SLE) patients, 86 and in SSc patients these MSCs were normal with respect to proliferation, clonogenicity and differentiation to bone and fat. 87 However, one group has shown defective differentiation into endothelial precursors in BM-derived MSCs from SSc patients, 88 which should be considered when choosing autologous or allogeneic MSC sources for SSc treatment. In another study, MSCs isolated from MS patients exhibit the same properties of MSCs from healthy donors in terms of proliferation, phenotype, in vitro differentiation and immunosuppressive ability. 89 All together, these results support the utilization of autologous MSCs from autoimmune patients for transplantation purposes.
However, the potential cancer-related risks of MSCs infusion should be cautiously considered. In fact, MSCs are being tested widely as potential agents for increasing neovascularization in critical ischemia settings, with the Mesenchymal stromal cells for autoimmune diseases A Tyndall and A Uccelli attendant risk of increasing tumour growth. 90 MSC may also play a role in reducing tumour surveillance, as shown in a murine melanoma model. 91 Finally, in vitro MSCs manipulation may increase the risk of cytogenetic abnormalities that may result in cancer development upon in vivo administration as reported in mice. 92 Currently, few peer-reviewed publications containing the results of using MSCs in human autoimmune disease are available. A small series of 10 MS patients from Iran was reported using autologous intrathecal MSCs. As the clinical results were mixed, the conclusion was that the use of autologous intrathecal MSCs was feasible. 93 An anecdotal report of MSC administration, intrathecally and i.v., in MS participants and patients with amyotrophic lateral sclerosis has been published providing evidence of the safety of such a treatment. 94 A small study of Crohn's disease has been announced by Osiris 95 -details of the outcome are not yet available.
Several issues need to be evaluated for human MSC trials in AD; in some countries cells manipulated ex vivo in animal protein containing media such as fetal bovine serum are not permitted. Human platelet lysate seems a valid alternative. 96 
Ongoing studies and future directions
There are a few running phase I clinical trials in AD including MS and Crohn's disease, with discussions underway concerning other AD such as type 1 diabetes mellitus, systemic sclerosis, vasculitis and SLE.
The setting of clear therapeutic targets and harmonization of cell products, especially MSC source and type (autologous or allogeneic), cell expansion conditions and trial protocols is important. In addition, long-term safety data collection across disciplines is required and an international interdisciplinary registry of MSC-treated patients has been launched. 97 
Conclusion
There are now data to suggest that the benefit/risk ratio for MSCs in humans is acceptable, mostly derived from acute GVHD studies. The fact that the conditioning of the patient with cytotoxic and other immunosuppressive agents is not necessary before MSC infusion, makes such a treatment attractive in a critically ill patient who would be unable to undergo an autologous hematopoietic stem cell transplant, an alternative strategy for severe AD.
Choice of patient, that is, multi-system, inflammatory disease similar to acute GVHD, or less active end-stage disease depends on whether the aim of the study is efficacy or feasibility/safety, respectively.
The immune privilege of MSCs is not guaranteed in an immune competent host, but that may not be important if the MSCs home to the target organ and survive long enough to exert a positive therapeutic effect.
Clearly, an international, coordinated and interdisciplinary effort is required to achieve robust data on a largeenough cohort of patients necessary to understand the proper role of MSCs treatment among the current therapeutic options for autoimmune diseases.
